Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMIT-iGL: iGlarLixi for Type 2 Diabetes Remission
NCT03130426Phase 3Completed
- Sponsor
- Population Health Research Institute
- Start
- Jun 2017
- Primary completion
- Jun 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM), sponsored by Population Health Research Institute. Started Jun 2017; status: completed.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03130426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03130426.